Pharmacokinetics of darifenacin, an M3 selective receptor antagonist

effects of renal or hepatic impairment

  • Devineni, D.
  • Skerjanec, A.
  • Greig, G.
  • G., T.

  • Novartis Pharmaceuticals, East Hanover, New Jersey, USA

British Journal of Clinical Pharmacology 59(5):p 632-633, May 2005.
Copyright © 2005 Blackwell Publishing Ltd.
View full text|Download PDF